CellProthera

Focus: CellProthera is a French biotech company specializing in stem cell transplantation therapies for cardiac conditions, headquartered in Mulhouse with a legacy dating to 1811. The company focuses on innovative cell therapy approaches to treat acute myocardial infarction and related heart disease.

Cell Therapy Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CellProthera

AI assessmentNot Hiring

No open roles listed right now. Follow CellProthera to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NA - Observational study

Acute Myocardial Infarction

N/A

Clinical Trials (1)

NCT06521047A Multicentre Observational Study to Assess Long-term Outcome of Participants in the EXCELLENT Clinical Trial

N/A

Help build intelligence for CellProthera

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering cell therapy modality in high-unmet-need cardiovascular space with Phase 1/2 and Phase 2 programs in clinical development
Long-established company (founded 1811) with institutional credibility and European regulatory expertise in a differentiated therapeutic area
Ground-floor opportunity to build infrastructure and establish your reputation in emerging stem cell transplant field

Watch Out For

No current active job openings (activeJobCount = 0) signals minimal hiring momentum or potential organizational constraints
Pre-clinical/early-stage pipeline with only Phase 1/2 programs; no Phase 3 data or revenue-generating products means distant commercialization and long path to cash flow
No disclosed funding, financial data, or employee count raises transparency concerns about company stability and runway

Generated by Claude from CellProthera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Lenograstim

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05594433Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte)

Phase 1

Protheracytes

Heart Attack

Phase 1/2

Clinical Trials (1)

NCT04198883SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand)

Phase 1/2

PROTHERACYTES

Acute Myocardial Infarction

Phase 2

Clinical Trials (1)

NCT02669810EXCELLENT (EXpanded CELL ENdocardiac Transplantation)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1811

Portfolio: 4 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo